- Home
- OMC vs NBIX Comparison
OMC vs NBIX Comparison
Compare OMC & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMC
- NBIX
- Stock Information
- Founded
- OMC 1944
- NBIX 1992
- Country
- OMC United States
- NBIX United States
- Employees
- OMC N/A
- NBIX N/A
- Industry
- OMC Advertising
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OMC Consumer Discretionary
- NBIX Health Care
- Exchange
- OMC Nasdaq
- NBIX Nasdaq
- Market Cap
- OMC 14.9B
- NBIX 14.4B
- IPO Year
- OMC N/A
- NBIX 1996
- Fundamental
- Price
- OMC $79.53
- NBIX $136.19
- Analyst Decision
- OMC Buy
- NBIX Strong Buy
- Analyst Count
- OMC 7
- NBIX 17
- Target Price
- OMC $96.29
- NBIX $163.71
- AVG Volume (30 Days)
- OMC 3.8M
- NBIX 895.4K
- Earning Date
- OMC 10-14-2025
- NBIX 10-29-2025
- Dividend Yield
- OMC 3.51%
- NBIX N/A
- EPS Growth
- OMC N/A
- NBIX 2.97
- EPS
- OMC 7.00
- NBIX 3.39
- Revenue
- OMC $15,910,800,000.00
- NBIX $2,509,900,000.00
- Revenue This Year
- OMC $4.79
- NBIX $20.75
- Revenue Next Year
- OMC $9.15
- NBIX $14.73
- P/E Ratio
- OMC $11.40
- NBIX $40.40
- Revenue Growth
- OMC 5.21
- NBIX 18.42
- 52 Week Low
- OMC $68.37
- NBIX $84.23
- 52 Week High
- OMC $107.00
- NBIX $154.61
- Technical
- Relative Strength Index (RSI)
- OMC 57.15
- NBIX 45.70
- Support Level
- OMC $75.81
- NBIX $135.59
- Resistance Level
- OMC $82.96
- NBIX $148.00
- Average True Range (ATR)
- OMC 2.04
- NBIX 3.15
- MACD
- OMC 0.11
- NBIX -1.16
- Stochastic Oscillator
- OMC 61.25
- NBIX 6.69
About OMC Omnicom Group Inc.
Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, ad placement, and public relations. The firm operates globally, providing services in more than 70 countries; it generates more than one half of its revenue in North America and nearly 30% in Europe.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.